Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Bristol-Myers Squibb will enter into a collaborative agreement with AstraZeneca, in order to develop and commercialise Amylin’s existing portfolio of products, which has a main focus on the R ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol Myers Squibb is the century-old pharmaceutical giant that markets the oral blood thinner Eliquis in partnership with ...

The company said that as part of a broader strategic realignment of their development pipeline, which involves other licensed ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) on September 6 and set a price ...

Delayed diagnosis and treatment of CCCA result in insufficiently aggressive therapy and risks an avoidable consequence, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol Myers Squibb (NYSE: BMY) has struggled to manage ... with a portfolio of more than 30 products and an even larger clinical pipeline across fields like hematology, oncology, cardiology ...